Cannabotech's IntegrativePain products show an 80 to 100 percent reduction in inflammatory pain

– The mouse model study was conducted by Cannabotech’s scientific team led by Dr. Isaac Angel, a pharmacologist specializing in drug development

– The products are based on a combination of fungi and cannabinoids that have achieved powerful therapeutic effects with low concentrations of THC

– The treatment is expected to be launched in Israel, the US and the UK in the second half of 2022

HERZLIYA, Israel, February 28, 2022 /PRNewswire/ — Cannabotech, a biomedical company developing medicinal products based on cannabis and mushroom extracts, has released study results showing that the use of mushroom compounds in conjunction with cannabinoids achieves an 80-100 percent reduction in pain sensation.

In addition, the addition of defined concentrations of other cannabinoids allowed the use of lower concentrations of THC to achieve very high medicinal potency.

Treatment is expected to start in Israel, US and UK in the second half of 2022 and integrated with existing therapeutic protocols as part of Cannabotech’s Integrative Oncology solution. This would coincide with conventional chemotherapy and provide supporting scientific information to physicians.

Currently, about 50-80% of cancer patients receive additional integrative treatment (mainly herbal products, including cannabis) in addition to chemotherapy. The main reasons for using integrative products include boosting the immune system, improving treatment efficiency and reducing adverse events.[1],[2]

The Inflammatory Pain Mouse Model Study evaluated the effectiveness of IntegrativePain products designed to relieve pain, including that arising from an inflammatory source such as arthritis, back pain, or side effects of chemotherapy.

The results clearly showed that adding cannabinoids to THC and CBD significantly increases medicinal potency. The uniqueness of the products lies in their ability to achieve high potency with low THC/high CBD concentrations combined with defined concentrations of other cannabinoids such as THCV and CBG, engineered to deliver maximum medicinal efficiency without the unwanted “high”. ” reach. In addition, the results showed a significant decrease in pain intensity independent of a directly reduced level of inflammation, suggesting that the products directly affect pain mechanisms in addition to their anti-inflammatory activity.

The story goes on

In addition, the mushroom composition, which consists of seven extracts from different mushrooms, achieved very high potency, as did the cannabinoids, with impressive pain-relieving results on its own. As expected by the company, the combination of shroom and cannabinoid produced a stronger effect than each alone. This finding reinforces Cannabotech’s claim that treating the endocannabinoid system (using cannabinoids) together with other systems, such as the immune system (using fungi), produces an enhanced and more potent medicinal effect than either of these components individually.

The experiment also emphasized the importance of tailored treatment, with Cannabotech developing three pain management formulas: one for pain from an inflammatory source; another for pain of neuropathic origin; and one-third for pain from integrated sources. In fact, this experiment demonstrated the effectiveness of different products on inflammation and pain originating from sources of inflammation, as well as differences in effectiveness between products when it came to reducing pain from a source of inflammation, as tested in the study. Cannabotech is currently developing a personalization system to provide physicians with the information to help them make informed and tailored decisions with IntegrativePain products.

IntegrativePain products are part of Cannabotech’s Integrative Oncology line of products, designed to treat cancer patients and the side effects of chemotherapy. The study is part of a series of studies Cannabotech has conducted across all integrative oncology products that are expected to be completed in a few months.

Cannabotech CEO Elhanan shaken said, “This is a significant milestone in Cannabotech’s journey to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy in multiple cancer types and are part of the company’s goal to define a new standard for the medical cannabis industry.

“Pain is the leading indication among medicinal cannabis users. While most of the products on the market are bud-based cannabis with high concentrations of THC, Cannabotech presents another oil-based concept, rich in other active ingredients and whose unique composition shows excellent results without the unwanted side effects.”

DR Isaac EngelCannabotech’s pharmacology consultant, said: “Pain is one of the key problems that the healthcare industry has been trying to solve for decades. Most pain patients experience pain from a combined, partially inflammatory source, which significantly affects their quality of life.” Cannabotech’s products have shown increased efficacy in the current mouse model. We are encouraged by these results, which represent another important milestone in demonstrating the scientific feasibility of the products. We will continue to work to bring patients a cure.”

About Cannabotech:

Cannabotech is an Israeli biomedical company developing botanical solutions for preventive medicine and integrative oncology medicine. These solutions are based on combinations of active ingredients from the cannabis plant and fungi that act on two central systems in the human body: the endocannabinoid system and the immune system.

As part of the concept of integrative medicine, Cannabotech has over the past two years developed a series of 8 preparations aimed at helping patients with cancer and chronic pain, based on unique combinations of medicinal cannabis botanicals and fungal-based products. The company’s goal is to integrate the products into the existing treatment protocol of oncology patients once their development is complete.

At the same time, Cannabotech is working to develop a defined treatment protocol that will be made available to physicians and technology to customize treatment.



View original content:

SOURCE Cannabotech